Creative Medical Technology Holdings, Inc. Overview
Pro stress-test →Creative Medical Technology Holdings is a commercial-stage biotechnology company focusing on novel biological therapeutics in immunotherapy, endocrinology, urology, neurology, and orthopedics. The company announced regulatory approval in January 2026 for its BioDefense Inc. Burn Pit Initiative, enabling a national program to collect expanded molecular and cellular data from veterans affected by burn pit exposure. The company is pursuing AI-enabled regenerative medicine solutions addressing multi-billion-dollar market opportunities.
Strategic Profile
Pro stress-test →The Burn Pit Initiative is funded using existing partnerships (including Greenstone Biosciences), internal infrastructure, and prior vendor relationships to support AI-driven molecular modeling, iPSC development, and regenerative countermeasure work. CELZ-101 has received FDA Orphan Drug Designation for brittle Type 1 Diabetes, offering potential market exclusivity, with ongoing clinical trials in Type 1 Diabetes and chronic lower back pain representing multi-billion-dollar market opportunities. The company maintains a lean operational footprint with minimal dilution risk from near-term funding needs.
Competitive Landscape
Pro stress-test →CELZ competes in regenerative medicine and immunotherapy against larger, better-capitalized biotech firms. Direct competitors in stem cell therapeutics include Mesoblast, Fate Therapeutics, and Moderna (cell therapy division). The company's narrow market focus on orphan indications (brittle Type 1 Diabetes) and specialized applications (burn pit exposure recovery) positions it as a niche player with less head-to-head competition but limited addressable markets.
Industry Context
Creative Medical Technology Holdings, Inc. operates in Regenerative medicine and cell therapy.
Key facts
Founded: Not specified in sources · Headquarters: Phoenix, US · Employees: 4 · Revenue: Not publicly disclosed · Market cap: $7.87M